3D Medicines (HKSE:01244) ROCE %: -30.58% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01244 3D Medicines Inc HKSE:01244
49 GF Score
Price HK$2.02
GF Value HK$3.15
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is 3D Medicines ROCE %?

3D Medicines HKSE:01244 +3.33% 49 ROCE % is -30.58% as of Dec. 2025. GuruFocus rates HKSE:01244 with a GF Score™ of 49/100 and a GF Value™ of HK$3.15 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. 3D Medicines's annualized ROCE % for the quarter that ended in Dec. 2025 was -30.58%.

3D Medicines  (HKSE:01244) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

3D Medicines ROCE % Related Terms

3D Medicines ROCE % Historical Data

* Premium members only.

The historical data trend for 3D Medicines's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3D Medicines ROCE % Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial 0.00 0.00 -58.25 -22.61 -28.63

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only -79.65 -24.16 -20.25 -26.51 -30.58
HKSE:01244
49GF Score
3D Medicines Inc HKSE:01244
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3D Medicines ROCE % Calculation

3D Medicines's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-198.535/( ( (1298.563 - 520.798) + (1034.29 - 425.23) )/ 2 )
=-198.535/( (777.765+609.06)/ 2 )
=-198.535/693.4125
=-28.63 %

3D Medicines's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-199.576/( ( (1248.246 - 551.871) + (1034.29 - 425.23) )/ 2 )
=-199.576/( ( 696.375 + 609.06 )/ 2 )
=-199.576/652.7175
=-30.58 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -30.58% mean?
3D Medicines (HKSE:01244) has a ROCE % of -30.58% as of Dec. 2025.
Is 3D Medicines' ROCE % too high?
3D Medicines' current ROCE % is -30.58%. Overall, 3D Medicines has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' ROCE % compare to VRTX and REGN?
3D Medicines' ROCE % of -30.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. 3D Medicines's current ROCE % is -30.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.15, compared to a current price of HK$2.02 — trading 36% below its estimated fair value. The current ROCE % is -30.58%. 3D Medicines' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current ROCE % is -30.58% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3D Medicines (HKSE:01244) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued. The current stock price of HK$2.02 is trading 36% below its estimated GF Value™ of HK$3.15. GuruFocus considers 3D Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01244:

  • ROCE %: -30.58%
  • GF Value™: HK$3.15 vs. price of HK$2.02 (36% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

3D Medicines Business Description

Address No. 3 and No. 5, Laiyang Road, Shandong Province, Shinan District, Qingdao, CHN
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
49GF Score

Get the complete analysis for HKSE:01244

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.02
Price
HK$3.15
GF Value